Register Login

Ocuphire Pharma Inc. (OCUP)

(90% Positive) Opus Genetics, Inc. (OCUP) Announces Enrollment Update for qualify Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 12:14 p.m.

    📋 Opus Genetics, Inc. (OCUP) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 07:10:52

    Event Type: Clinical Trial Update

    Event Details:

    Ocuphire Pharma Inc. (OCUP) Announces Clinical Trial Update Ocuphire Pharma Inc. (OCUP) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: qualify, blindness
    • Diseases/Conditions: Rare Pediatric Disease designation, Priority Review Vouchers (PRV)
    • Clinical Stage: clinical trial
    • Collaboration: Priority Review Vouchers
      • targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
      • anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024
      • anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. Contacts: Investors Jenny Kobin Remy Bernarda IR Advisory Solutions ir@opusgtx.com Media Kimberly Ha KKH Advisors 917-291-5744

    🔬 Clinical Development Pipeline (Opus Genetics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    OPGx-BEST1 GENETIC Phase PHASE1 ARB ClinicalTrials.gov
    AAV8.hLCA5 BIOLOGICAL Phase PHASE1 LCA5 ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ocuphire Pharma Inc.
    • CIK: 0001228627
    • Ticker Symbol: OCUP
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories